306 related articles for article (PubMed ID: 15701824)
21. Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Wang N; Sun P; Lv M; Tong G; Jin X; Zhu X
Biomater Sci; 2017 May; 5(5):1041-1050. PubMed ID: 28378865
[TBL] [Abstract][Full Text] [Related]
22. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.
Etame AB; Diaz RJ; Smith CA; Mainprize TG; Hynynen K; Rutka JT
Neurosurg Focus; 2012 Jan; 32(1):E3. PubMed ID: 22208896
[TBL] [Abstract][Full Text] [Related]
23. Perspectives on Dual Targeting Delivery Systems for Brain Tumors.
Gao H
J Neuroimmune Pharmacol; 2017 Mar; 12(1):6-16. PubMed ID: 27270720
[TBL] [Abstract][Full Text] [Related]
24. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes.
Gao JQ; Lv Q; Li LM; Tang XJ; Li FZ; Hu YL; Han M
Biomaterials; 2013 Jul; 34(22):5628-39. PubMed ID: 23628475
[TBL] [Abstract][Full Text] [Related]
25. Malignant Intracranial High Grade Glioma and Current Treatment Strategy.
Zhang X; Zhang W; Mao XG; Cao WD; Zhen HN; Hu SJ
Curr Cancer Drug Targets; 2019; 19(2):101-108. PubMed ID: 29848277
[TBL] [Abstract][Full Text] [Related]
26. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.
Hersh DS; Wadajkar AS; Roberts N; Perez JG; Connolly NP; Frenkel V; Winkles JA; Woodworth GF; Kim AJ
Curr Pharm Des; 2016; 22(9):1177-1193. PubMed ID: 26685681
[TBL] [Abstract][Full Text] [Related]
27. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review.
Lossinsky AS; Shivers RR
Histol Histopathol; 2004 Apr; 19(2):535-64. PubMed ID: 15024715
[TBL] [Abstract][Full Text] [Related]
28. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.
Linzey JR; Marini BL; Pasternak A; Smith C; Miklja Z; Zhao L; Kumar-Sinha C; Paul A; Harris N; Robertson PL; Hoffman LM; Chinnaiyan A; Mody R; Koschmann C
J Neurooncol; 2018 Mar; 137(1):155-169. PubMed ID: 29235051
[TBL] [Abstract][Full Text] [Related]
29. Blood-brain barrier and chemotherapeutic treatment of brain tumors.
de Vries NA; Beijnen JH; Boogerd W; van Tellingen O
Expert Rev Neurother; 2006 Aug; 6(8):1199-209. PubMed ID: 16893347
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutics for brain tumors: current practice and future prospects.
El Demerdash N; Kedda J; Ram N; Brem H; Tyler B
Expert Opin Drug Deliv; 2020 Jan; 17(1):9-21. PubMed ID: 31971041
[No Abstract] [Full Text] [Related]
32. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN; Hu LS; Parney IF; Pafundi DH; Brinkmann DH; Laack NN; Giannini C; Burns TC; Kizilbash SH; Laramy JK; Swanson KR; Kaufmann TJ; Brown PD; Agar NYR; Galanis E; Buckner JC; Elmquist WF
Neuro Oncol; 2018 Jan; 20(2):184-191. PubMed ID: 29016900
[TBL] [Abstract][Full Text] [Related]
33. Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier.
Omidi Y; Kianinejad N; Kwon Y; Omidian H
Expert Rev Clin Pharmacol; 2021 Mar; 14(3):357-381. PubMed ID: 33554678
[No Abstract] [Full Text] [Related]
34. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
Hendricks BK; Cohen-Gadol AA; Miller JC
Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
[TBL] [Abstract][Full Text] [Related]
35. Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System.
Naidoo J; Panday H; Jackson S; Grossman SA
Oncology (Williston Park); 2016 Nov; 30(11):953-62. PubMed ID: 27854097
[TBL] [Abstract][Full Text] [Related]
36. Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.
Tosi U; Marnell CS; Chang R; Cho WC; Ting R; Maachani UB; Souweidane MM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208698
[TBL] [Abstract][Full Text] [Related]
37. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound.
Kinoshita M; McDannold N; Jolesz FA; Hynynen K
Biochem Biophys Res Commun; 2006 Feb; 340(4):1085-90. PubMed ID: 16403441
[TBL] [Abstract][Full Text] [Related]
38. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
39. L-Borneol induces transient opening of the blood-brain barrier and enhances the therapeutic effect of cisplatin.
Yin Y; Cao L; Ge H; Duanmu W; Tan L; Yuan J; Tunan C; Li F; Hu R; Gao F; Feng H
Neuroreport; 2017 Jun; 28(9):506-513. PubMed ID: 28471848
[TBL] [Abstract][Full Text] [Related]
40. C-type natriuretic peptide-modified lipid vesicles: fabrication and use for the treatment of brain glioma.
Wu JS; Mu LM; Bu YZ; Liu L; Yan Y; Hu YJ; Bai J; Zhang JY; Lu W; Lu WL
Oncotarget; 2017 Jun; 8(25):40906-40921. PubMed ID: 28402948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
